SpringWorks Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SWTX Nasdaq 8731 https://www.springworkstx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SpringWorks Therapeutics Inc

SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA - Jun 5th, 2023 10:30 am
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors - May 30th, 2023 10:30 am
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting - May 25th, 2023 9:05 pm
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit - May 24th, 2023 11:00 am
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress - May 11th, 2023 4:14 pm
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights - May 3rd, 2023 10:30 am
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference - May 2nd, 2023 11:00 am
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 - Apr 17th, 2023 6:32 pm
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 - Apr 17th, 2023 6:30 pm
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors - Mar 8th, 2023 10:05 pm
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference - Mar 1st, 2023 12:00 pm
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights - Feb 28th, 2023 11:30 am
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors - Feb 27th, 2023 11:30 am
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference - Jan 9th, 2023 11:30 am
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 12:00 pm
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors - Dec 27th, 2022 11:30 am
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference - Nov 22nd, 2022 12:00 pm
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Nov 3rd, 2022 10:30 am
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma - Nov 1st, 2022 3:07 pm
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors - Sep 29th, 2022 10:30 am